Lung Disease Clinical Trial
Official title:
A Fast-track Randomised Controlled Trial to Evaluate a Hospital2Home Palliative Care Service for Patients With Advanced Progressive Idiopathic Fibrotic Interstitial Lung Disease
The investigators hypothesise that H2H will result in improved symptom control and quality
of life and may be more cost-effective than standard best practice.
Interstitial Lung Disease (ILD) is a lung condition characterised by progressive scarring -
known as fibrosis. This is especially seen in patients with idiopathic pulmonary fibrosis
(IPF). There around 2,000 new patients diagnosed in the UK every year with a similar number
of deaths.
Fibrotic-ILD causes breathing to slowly deteriorate and as there is no cure, an estimated
two-thirds of patients die within five years of diagnosis. Patients suffer from many
symptoms including shortness of breath, cough, low mood and fatigue which are currently
being poorly managed. In addition, these patients suffer a poor health related quality of
life whilst dying from their disease.
In the later stages of their disease, these patients often end up in hospital (see appendix
1a) when there is no proven or effective treatment. Many die there despite wishing to be
looked after and die at home. These patients rarely receive palliative care which may help
to improve their symptoms, quality of life, address end of life planning needs and prevent
hospital admission. The Hospital2Home case conference conducted in the patient's home (or
place of their choice) aims to address this. At the case conference involving the patient,
their carers, a specialist nurse, and all the community health professionals, a care plan
specific to the patient will be developed. Each health professional will be aware of their
responsibility and duties. The investigators will look at whether this results in better
symptom control and better quality of life for the patient and their carer. The
investigators will also examine whether this prevents emergency hospital admission and
allows patients to die in their preferred place. The investigators will compare patients who
receive the service immediately with those who receive it after a delay.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217423 -
Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT01679301 -
Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Terminated |
NCT00966823 -
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
|
Phase 2 | |
Completed |
NCT00139152 -
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
|
Phase 4 | |
Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Recruiting |
NCT02963467 -
Effect of Smoking on Ventilation-Perfusion Ratio
|
N/A | |
Recruiting |
NCT02965300 -
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis
|
N/A | |
Enrolling by invitation |
NCT02946658 -
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT01735526 -
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation
|
N/A | |
Completed |
NCT01952002 -
Clinical Safety for the Inspiratory Muscle Training
|
N/A | |
Completed |
NCT01153321 -
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT01215279 -
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
|
Phase 2 | |
Completed |
NCT00837681 -
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
Completed |
NCT01222442 -
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
|
Phase 1 | |
Recruiting |
NCT02723474 -
A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease
|
N/A |